BRIEF-BioVie says first patient dosed in trial for refractory ascites due to liver cirrhosis

* BioVie announces first patient dosed with BIV201 in Phase 2A clinical trial for refractory ascites due to liver cirrhosis Source text for Eikon: Further company coverage:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.